Potentiated antitumor effects of APS001F/5-FC combined with anti-PD-1 antibody in a CT26 syngeneic mouse model.

APS001F is a strain of Bifidobacterium longum genetically engineered to express cytosine deaminase that converts 5-fluorocytosine (5-FC) to 5-fluorouracil. In the present study, antitumor effects of APS001F plus 5-FC (APS001F/5-FC) in combination with anti-PD-1 monoclonal antibody were investigated using a CT26 syngeneic mouse model. Both of dosing of APS001F/5-FC before and after anti-PD-1 mAb in the combination dosing exhibited antitumor effects as well as prolonged survival over the nontreated control. The survival rate in the combination therapy significantly increased over the monotherapy with APS001F/5-FC and that with anti-PD-1 mAb. Regulatory T cells among CD4+ T cells in tumor decreased in the combination therapy, while the ratio of CD8+ T cells was maintained in all groups. Taken these results together, APS001F/5-FC not only demonstrates a direct antitumor activity, but also immunomodulatory effects once localized in the hypoxic region of the tumor, which allows anti-PD-1 mAb to exert potentiated antitumor effects.

[1]  M. Minopoli,et al.  Tumor Associated Neutrophils. Their Role in Tumorigenesis, Metastasis, Prognosis and Therapy , 2019, Front. Oncol..

[2]  M. Xie,et al.  Role of hypoxia in cancer therapy by regulating the tumor microenvironment , 2019, Molecular Cancer.

[3]  Xiaomo Wu,et al.  Application of PD-1 Blockade in Cancer Immunotherapy , 2019, Computational and structural biotechnology journal.

[4]  I. Furtado,et al.  Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer , 2019, Front. Oncol..

[5]  J. Schellens,et al.  Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  E. V. Van Allen,et al.  Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine , 2018, Genome Medicine.

[7]  Vanessa M. Hubbard-Lucey,et al.  Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors , 2018, Nature Reviews Drug Discovery.

[8]  J. Utikal,et al.  Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression , 2018, British Journal of Cancer.

[9]  E. Matera,et al.  The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent , 2018, Front. Immunol..

[10]  S. Walmsley,et al.  The role of neutrophils in cancer , 2018, British medical bulletin.

[11]  Stephen T. C. Wong,et al.  Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival. , 2018, JCI insight.

[12]  K. Kabashima,et al.  Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations , 2018, Front. Oncol..

[13]  B. Ryffel,et al.  PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer , 2018, Oncoimmunology.

[14]  C. Fenselau,et al.  Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment , 2018, The Journal of Immunology.

[15]  G. Kochan,et al.  Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy. , 2017, Annals of translational medicine.

[16]  W. Ma,et al.  Immunotherapy for Colorectal Cancer , 2017, Cancers.

[17]  D. Cua,et al.  Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy. , 2017, Cancer research.

[18]  Chunxiao Zhou,et al.  Repeated cycles of 5-fluorouracil chemotherapy impaired anti-tumor functions of cytotoxic T cells in a CT26 tumor-bearing mouse model , 2016, BMC Immunology.

[19]  A. Korman,et al.  Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology , 2016, PloS one.

[20]  H. Harada.  Hypoxia-inducible factor 1–mediated characteristic features of cancer cells for tumor radioresistance , 2016, Journal of radiation research.

[21]  Megan Cully.  Trial watch: Combinations with checkpoint inhibitors at wavefront of cancer immunotherapy , 2015, Nature Reviews Drug Discovery.

[22]  L. Zitvogel,et al.  Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. , 2013, Immunity.

[23]  Chunxiao Zhou,et al.  Immunotherapy using slow-cycling tumor cells prolonged overall survival of tumor-bearing mice , 2012, BMC Medicine.

[24]  Yasushi Okuno,et al.  Adverse Event Profiles of 5-Fluorouracil and Capecitabine: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations , 2011, International journal of medical sciences.

[25]  D. Schadendorf,et al.  Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model , 2011, Proceedings of the National Academy of Sciences.

[26]  H. Tsutsui,et al.  Targeting solid tumors with non‐pathogenic obligate anaerobic bacteria , 2010, Cancer science.

[27]  J. Vincent,et al.  5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. , 2010, Cancer research.

[28]  G. Cheng,et al.  Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. , 2009, Cancer cell.

[29]  Yoshinori Hamaji,et al.  Genetically engineered Bifidobacterium longum for tumor‐targeting enzyme‐prodrug therapy of autochthonous mammary tumors in rats , 2006, Cancer science.

[30]  M. Colombo,et al.  Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. , 2006, Cancer research.

[31]  J. Gehl,et al.  Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model , 2005, British Journal of Cancer.

[32]  Takayuki Sasaki,et al.  Cloned Cytosine Deaminase Gene Expression of Bifidobacterium longum and Application to Enzyme/Pro-drug Therapy of Hypoxic Solid Tumors , 2002, Bioscience, biotechnology, and biochemistry.

[33]  Y. Kano,et al.  Bifidobacterium longum as a delivery system for cancer gene therapy: Selective localization and growth in hypoxic tumors , 2000, Cancer Gene Therapy.

[34]  Janice M. Y. Brown,et al.  The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. , 1999, Cancer research.

[35]  W. Spector.  Chronic inflammation. , 1977, Journal of endodontics.